Fulcrum Therapeutics, Inc. (FULC)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Fulcrum Therapeutics, Inc. reported revenue of $0, down 100.0% from the prior year. The company ran a net loss. It held $366.28M in total assets against $17.28M in total liabilities.
Key ratios (FY2025)
-21.5%
Return on equity
-100.0%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $80.00M | $2.81M | $6.34M | $19.16M | $8.82M | — | — | — |
| Operating Income | -$84.77M | -$21.90M | -$110.66M | -$112.56M | -$81.05M | -$71.61M | -$84.22M | -$33.50M | — |
| Net Income | -$74.88M | -$9.72M | -$97.33M | -$109.87M | -$80.85M | -$70.82M | -$82.68M | -$32.59M | — |
| EPS (Diluted) | $-1.18 | $-0.16 | $-1.59 | $-2.44 | $-2.29 | $-2.79 | — | — | — |
| Total Assets | $366.28M | $260.72M | $257.69M | $226.69M | $235.00M | $129.58M | $110.44M | $85.77M | — |
| Total Liabilities | $17.28M | $17.68M | $22.50M | $27.74M | $23.46M | $34.40M | $23.29M | $9.77M | — |
| Shareholders' Equity | $349.00M | $243.03M | $235.19M | $198.94M | $211.54M | $95.18M | $87.15M | -$63.67M | -$33.27M |
| Cash & Equivalents | $197.53M | $58.21M | $25.56M | $35.10M | $35.41M | $57.05M | $96.71M | $72.80M | — |
| Operating Cash Flow | -$60.06M | -$2.22M | -$90.97M | -$97.05M | -$78.48M | -$53.66M | -$39.48M | -$22.56M | — |
| Capital Expenditures | $314.0K | $278.0K | $508.0K | $1.96M | $1.71M | $1.34M | $853.0K | $8.98M | — |
| Shares Outstanding | 66.58M | 53.97M | 61.92M | 52.10M | 40.63M | 27.94M | 22.65M | 1.59M | — |